BioInvent International AB

Oslo, 5 November 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the third quarter 2026. Webcast scheduled for 5 November 2026 at 09:00 (CET). Link to webcast here . Operational Highlights: ZIMA-101 recruitment and dosing on track: Two of the three patients required at Dose Level 1 have now been successfully dosed, the second following the reporting period, with dosing of a third patient planned during Q4 2026 to complete this dose level. More than 30 patients have been screened for HLA-A2 and/or MAGE-A4 expression, with potential patients identified across all four target indications (ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer), demonstrating strong clinical site engagement and supporting continued recruitment momentum. Subject to completion of Dose Level 1 and a favourable subsequent safety review by the Independent Data Monitoring Committee (IDMC), Zelluna expects to begin and complete recruitment and dosing at Dose Level 2, representing a threefold increase in the administered cell dose compared with Dose Level 1, during Q1 through early Q2 2027. No dose-limiting toxicities to date: ZI-MA4-1 has been well tolerated, with no dose-limiting toxicities reported in the two patients treated. On 17 August 2026, the Independent Data Monitoring Committee (IDMC) completed its planned safety review of the first patient and recommended continued recruitment at Dose Level 1. Initial observations from patient samples: Preliminary blood measurements indicate cell kinetics consistent with expectations, alongside early changes in circulating pro-inflammatory immune markers following ZI-MA4-1 infusion. Clinical follow-up is ongoing, including further tumour imaging assessments and the collection and analysis of translational data from patients treated at Dose Level 1. External clinical evidence supports TCR-NK therapeutic potential: Researchers at MD Anderson Cancer Center have reported a complete response in a heavily pre-treated multiple myeloma patient treated with an independently developed TCR-NK therapy. While generated in a different disease setting, this provides an encouraging external clinical demonstration that the TCR-NK approach can deliver anti-tumour activity in late-stage cancer patients. Awarded NOK 15.6 million grant by the Research Council of Norway to further advance TCR-NK manufacturing: Following the reporting period, on 4 November 2026, Zelluna was awarded NOK 15.6 million in a grant by the Research Council of Norway. Funding will enable further manufacturing development and support Zelluna's commercial strategy to make off-the-shelf TCR-NK cell therapies broadly accessible to patients with solid cancers. The award, which is subject to final contract negotiations, follows another grant awarded by the Research Council of Norway in June 2026 earlier this year to support the ZIMA-101 clinical programme. Manufacturing process successfully executed at new CDMO: Following the reporting period, an initial manufacturing run was successfully completed at Zelluna’s new CDMO, an important step towards establishing manufacturing capabilities at the new facility and highlighting the potential transferability of Zelluna’s manufacturing process across sites, an important TCR-NK platform attribute supporting future scalability, manufacturing flexibility and cost efficiency. Analytical and functional characterisation of the resulting product is ongoing. ZIMA-101 featured at leading international oncology conferences: Following the reporting period, the design of the ongoing ZIMA-101 Phase 1 study of ZI-MA4-1 was presented by Professor Fiona Thistlethwaite, Chief Investigator of the study at The Christie NHS Foundation Trust, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. A further poster presentation outlining the design of the study is scheduled for the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2026. Martin Welschof elected as new Board member: At an Extraordinary General Meeting held on 9 September 2026, Martin Welschof, CEO of BioInvent International AB, was elected as a new member of the Board, replacing Hans Ivar Robinson, who has stepped down from the Board. Martin Welschof has previously served as CEO of Affitech A/S and Opsona Therapeutics, holds a PhD in recombinant antibody technology and brings extensive international experience from executive leadership in clinical-stage and listed biotechnology companies. Financial Highlights Q3 2026: Total operating expenses: MNOK 28.8 in Q3 2026 and MNOK 69.2 YTD Total loss: MNOK 29.0 in Q3 2026 and MNOK 69.0 YTD Cash and cash equivalents: MNOK 60.4 as of 30 September 2026 Net negative cash flow from operations: MNOK 25.5 in Q3 2026 Financial runway: Into Q3 2027 Expected grants and tax credits: SkatteFUNN tax credits of MNOK 5.2 related to 2025 expected in Q4 2026, as well as the first payments under the MNOK 16 grant awarded by the Research Council of Norway in June 2026, with the remainder expected in 2027 Share issue to Inven2: On 4 August 2026, 446,752 new shares were issued at NOK 19.78 per share to settle EUR 791,666.70 under the option and license agreement with Inven2, triggered by the dosing of the first patient “The third quarter marked Zelluna’s transition into a clinical-stage biotechnology company. We have now treated two patients in ZIMA-101, with no dose-limiting toxicities reported to date. Recruitment is on track, supported by strong engagement from our clinical sites and investigators driving continued progress towards completion of our first dose cohort and preparations for dose escalation. Our immediate priority is to complete Dose Level 1 and progress towards a threefold higher dose, subject to independent safety review. This will be an important next step in exploring the therapeutic potential of TCR-NK for patients with solid tumours. We are also encouraged by emerging external clinical evidence, including the complete response reported with an independent TCR-NK therapy, demonstrating the potential of this approach to deliver meaningful anti-tumour activity in patients. With our differentiated platform, continued clinical execution, and sustained strategic interest in off-the-shelf cell therapies we believe Zelluna is well positioned to create value for patients and shareholders as clinical data builds” says CEO Namir Hassan. “It is encouraging to see the progress in recruitment to the ZIMA-101 study, with patients being identified across several solid tumour indications. As an early-phase clinical trial evaluating a novel TCR-NK cell therapy, our initial focus is on establishing safety and progressing through dose escalation. We look forward to building on this early experience as the study advances.” Prof. Fiona Thistlethwaite, Chief Investigator, ZIMA-101. Outlook Zelluna enters the final quarter of 2026 with encouraging initial clinical observations and recruitment and dosing progressing on track in the first-in-human ZIMA-101 study. The Company’s immediate priority is to complete Dose Level 1 and advance to Dose Level 2, where recruitment and dosing are expected to take place from Q1 through early Q2 2027, subject to completion of Dose Level 1 and a favourable subsequent IDMC safety review. The encouraging initial observations at the lowest planned dose level support continued dose escalation. Ongoing clinical and translational assessments of patients treated at Dose Level 1, together with data from higher dose levels, are expected to build a more comprehensive understanding of the safety and therapeutic potential of ZI-MA4-1. In parallel, Zelluna continues to strengthen its manufacturing capabilities and advance its TCR-NK pipeline, including the evaluation of AI-engineered TCR candidates targeting KKLC1. Zelluna's cash position is expected to fund planned operations into the third quarter of 2027. The quarterly report and presentation materials will be made publicly available on the Zelluna website at 07:00 CET on 5 November 2026. The Company will host a webcast on 5 November at 09:00 CET, and questions can be submitted during the event. The webcast recording will remain available on the Company's website after the event. For further information, please visit or contact: Namir Hassan, CEO Email: namir.hassan@zelluna.com Phone: +44 7720 687608 Geir Christian Melen, CFO Email: geir.christian.melen@zelluna.com Phone: +47 913 02 965 About Zelluna ASA Zelluna ASA (OSE: ZLNA) is a clinical-stage company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers. The Company's technology combines the natural tumour-killing ability of NK cells with precision targeting of solid tumours enabled by affinity-engineered T cell receptors (TCRs). The goal is to create effective, scalable and accessible treatments for patients with solid tumours – a patient population with significant unmet medical need. Zelluna is listed on the Euronext Oslo Stock Exchange under the ticker ZLNA and is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and the EU Market Abuse Regulation. Glossary TCR-NK: NK cells are immune cells that kill cancer cells. Zelluna equips them with a T cell receptor (TCR), which enables them to find specific cancer cells more precisely and efficiently. Allogeneic / "off-the-shelf": The cells come from healthy donors rather than from the patient. Many doses can be made at once, frozen and kept ready for use. MAGE-A4: A protein found in many types of cancer cells but hardly at all in healthy tissue, which makes it a good treatment target. HLA-A2: A tissue type the patient must have for ZI-MA4-1 to recognise the cancer cells. Patients are tested for this before they can take part. Dose level and dose escalation: Patients in the study are treated in groups of three, and the dose is increased step by step. Each group receives a higher dose than the previous one, but only after safety has been reviewed. Dose-limiting toxicity: A side effect so serious that the dose cannot be increased further. The absence of such effects means the study can continue as planned. IDMC: An independent committee of experts that monitors patient safety and decides whether the study can proceed. Cell kinetics: How the infused cells behave in the blood over time. Pro-inflammatory immune markers: Signalling molecules in the blood that show the immune system has been activated. Translational data: Analyses of blood and tissue samples that show what the treatment does biologically in the body. Complete response: Cancer can no longer be detected after treatment. Multiple myeloma: A type of blood cancer that affects the bone marrow. KKLC1: Another protein found in cancer cells and a potential target for Zelluna's next products Attachments Zelluna-ASA-Q326-Report Zelluna-ASA-Q326-Presentation

“Our clinical portfolio remains focused on two targets, TNFR2 and FcγRIIB, but with a current priority on BI-1808 in cancers where patients have few effective options. With the planned rights issue and a leaner organization, we aim to secure the resources to advance BI-1808 into randomized and potentially pivotal studies."- Martin Welschof, CEO BioInvent. EVENTS DURING THE THIRD QUARTER BI-1808 received FDA Fast Track Designation for the treatment of ovarian cancer BioInvent’s BI-1808 abstract from Modest to Meaningful in platinum-resistant ovarian cancer accepted for poster presentation at ESMO 2026 BioInvent published two scientific papers in peer-reviewed journals. One in Cancer Research: “Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity” and one in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models EVENTS AFTER THE END OF THE PERIOD (R) The Board of Directors has decided to carry out a rights issue of approximately SEK 430 million (gross, before issue costs), of which SEK 350 million is covered by subscription commitments and guarantee undertakings, subject to approval at an Extraordinary General Meeting (R) Streamlining of the organization to support prioritized clinical programs (R) BI-1808 and KEYTRUDA® induce durable responses in heavily pretreated platinum-resistant ovarian cancer. The poster was granted Best Poster Award, Investigational Immunotherapy at ESMO 2026 (R) The company announced that its CFO will retire in 2027 First-in-Human BI-1808 Data Published in Clinical Cancer Research (R)= Regulatory event FINANCIAL INFORMATION Third quarter 2026 Net sales SEK 10.8 (3.3) million. Profit/loss after tax SEK -118.9 (-129.2) million Profit/loss after tax per share before and after dilution SEK -1.81 (-1.96). Cash flow from operating activities SEK-113.5 (-104.0) million. January – September 2026 Net sales SEK 37.0 (223.5) million. Profit/loss after tax SEK -361.0 (-207.1) million. Profit/loss after tax per share before and after dilution SEK -5.49 (-3.15). Cash flow from operating activities SEK -358.3 (-157.2) million. Liquid funds, current and long-term investments as of September 30, 2026: SEK 224.6 (690.5) million. The complete interim report is available for download below and on the company’s website under Financial reports. INVITATION TO PRESENTATION OF THE INTERIM REPORT BioInvent’s CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When: Thursday October 29, 2026, at 3:00 pm CET The webcast can be reached at https://events.inderes.com/bioinvent/q3-report-2026. If you wish to ask questions and participate via telephone, please register at the link below. After registration you will be provided with a phone number and a conference ID to access the conference. https://events.inderes.com/bioinvent/q3-report-2026/dial-in. The conference call will be made available on the company website after the call. About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. For further information, please contact: Cecilia Hofvander, VP Investor Relations Phone: +46 (0)46 286 85 50 Email: cecilia.hofvander@bioinvent.com BioInvent International AB (publ) Co. Reg. No.: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 www.bioinvent.com

BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care 24% objective response rate (8 of 34 evaluable patients: 1 complete and 7 partial responses), including patients with high-grade serous and clear cell carcinoma53% disease control rate, with several patients in stable disease beyond 10 months; 6 patients were still on treatment at data cutoffMedian progression-free survival of 4.1 months per RECIST, compared with 2.1 months reported for pembrolizumab alone1 (indirect comparison); 10.3 months per iRECISTDuration of response was not met at cutoff (median follow-up 11.6 months), suggesting that responses are durableWell tolerated: fewer than 5% treatment-related discontinuations among 81 solid tumor patients treated with the combinationPart C will add BI-1808 to pembrolizumab plus weekly paclitaxel ± bevacizumab in a randomized design; first data expected in H2 2027 October 24, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced updated data from Part B of its ongoing clinical study of BI-1808, a first-in-class anti-TNFR2 antibody, combined with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced platinum-resistant recurrent ovarian cancer (PRROC) and a median of four prior lines of therapy. The data are presented today in poster #2009P (12:00-12:45 CEST) at the ESMO Congress 2026 in Madrid. They update the 25-patient analysis reported at ASCO 2026, the ESMO abstract published on October 19 and now include 34 evaluable patients (cutoff September 14, 2026). Checkpoint inhibitors alone have limited activity in PRROC because CD8+ T cells poorly infiltrate the tumor microenvironment, where immunosuppressive TNFR2-expressing cells such as regulatory T cells (Tregs) and tumor-associated myeloid cells are enriched and further suppress antitumor T-cell activity. BI-1808 is a ligand-blocking, FcγR-engaging TNFR2 antibody designed to deplete these Tregs and remodel the myeloid compartment, promoting activation, expansion and infiltration of anti-tumoral CD8+ T cells. "Patients with platinum-resistant ovarian cancer have few therapeutic options, and checkpoint inhibitors alone have done little to change that," said Martin Welschof, Chief Executive Officer at BioInvent. "With Part B complete, a 24% response rate and durable disease control in heavily pretreated patients suggest that targeting TNFR2 can add significant activity when combined with immune checkpoint inhibition. Our next step will be to evaluate BI-1808 as an add-on to the newly established pembrolizumab and paclitaxel backbone in a randomized Part C." The 34 evaluable patients (of 40 planned) had a median age of 62 years and had received a median of four prior lines of therapy; 88% had received three or more, and all had received platinum. Histology was high-grade serous adenocarcinoma (HGSA) in 59% and clear cell in 41%, and 24% had liver involvement at screening. They were treated with BI-1808 1000 mg plus pembrolizumab 200 mg every three weeks for up to two years. Responses were seen in both HGSA and clear cell ovarian cancer, including in patients with active liver metastases.In some patients, tumors grew before shrinking. This may reflect pseudoprogression (an apparent increase in size caused by immune cells entering the tumor) or a delay in CD8+ T-cell expansion, an observation previously made in preclinical models (ASCO#2605 poster).Most cases of progressive disease were not confirmed on a follow-up scan. These patients left the study with unconfirmed progressive disease under iRECIST, which explains the difference between PFS and iPFS. What is iRECIST? iRECIST is an adaptation of the standard RECIST criteria for immunotherapies. It requires confirmation of progression before treatment is stopped, so it can capture responses that appear after initial apparent tumor growth. Median PFS by iRECIST may therefore be longer than by RECIST. In KEYNOTE-100, pembrolizumab alone produced an objective response rate of 8% and a disease control rate of 37%. Median progression-free survival was 2.1 months by RECIST 1.1, and no iRECIST-based figure was reported. 81 patients with solid tumors have received BI-1808 plus pembrolizumab to date Immune-related adverse events were manageable, and the rate of Grade 3 or higher adverse events was low Treatment-related discontinuations in the combination arm occurred in 4 patients (fewer than 5%) Reduced Tregs in the blood of ovarian cancer patients, and a shift in the CD8+ T-cell over Treg ratio in tumor biopsies Induction of IL-12 and CXCL10, cytokines associated with myeloid reprogramming, proinflammatory activation, and effector T cell recruitment Induction of CCL19 and CXCL13, chemokines associated with tertiary lymphoid structure (TLS) formation Proinflammatory myeloid and TLS-stimulating cytokines were strongly potentiated when BI-1808 was combined with pembrolizumab 2 Next step: adding BI-1808 to pembrolizumab and paclitaxelThe KEYNOTE-B96 study 3 recently added an immunotherapy option to the standard weekly paclitaxel ± bevacizumab regimen in platinum-resistant ovarian cancer, improving median PFS (8.3 vs 7.2 months) and overall survival (17.7 vs 14.0 months) versus chemotherapy alone. This creates a backbone on which to test additional mechanisms. In a mouse model of ovarian cancer (ID8), the combination of a BI-1808 surrogate antibody, paclitaxel and anti-PD-1 improved survival, with increases in serum cytokines indicating myeloid reprogramming and TLS formation. Part C of the study will randomize 20 patients to each of three arms: BI-1808 1000 mg, BI-1808 500 mg, or control, each with pembrolizumab and weekly paclitaxel +/- bevacizumab. Part C is expected to start in Q1 2027, with first data in H2 2027, subject to enrollment. Poster detailsTitle: From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer (PRROC)Poster number: 2009P | Session: Investigational immunotherapyDate and time: October 24, 12:00-12:45 CESTFirst author: Rebecca Kristeleit, Guy's and St Thomas' NHS Foundation Trust, United Kingdom The BI-1808 study (NCT04752826, KEYNOTE-D20) is an ongoing open-label Phase 1/2a study evaluating BI-1808 as a single agent (Part A), in combination with pembrolizumab (Part B) and in combination with pembrolizumab and paclitaxel ± bevacizumab (Part C). Patients were enrolled at 14 study locations in Europe and the United States. Clinical trial collaboration and supply agreementKEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Since August 2021, BioInvent has a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate the combination of BI-1808 and MSD's anti-PD-1 therapy KEYTRUDA (pembrolizumab). Ovarian cancer is a serious and life-threatening disease, affecting more than 320,000 women worldwide each year. 4 It is frequently diagnosed at an advanced stage because its symptoms are often difficult to recognize, and is the eighth most common cancer and the eighth leading cause of cancer-related death among women globally. 5 Recurrence affects an estimated 70-90% of patients with advanced disease after initial treatment. 6 Five-year survival rate is estimated at 50%, across all stages, types and regions. 7,8 BI-1808 is a first-in-class drug candidate targeting TNFR2, which is upregulated on both immunosuppressive and inflammatory tumor-infiltrating lymphocytes and on myeloid cells in the tumor microenvironment. BI-1808 is in clinical development for T-cell lymphoma and solid tumors, and has shown single-agent activity and excellent tolerability, and efficacy and a favorable safety profile in combination with pembrolizumab. BI-1808 has received FDA Fast Track Designation for the treatment of ovarian cancer and for relapsed or refractory mycosis fungoides and Sézary syndrome, FDA Orphan Drug Designation for T-cell lymphoma, and Orphan Drug Designation in cutaneous T-cell lymphoma from the European Medicines Agency. BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of solid tumors and hematological cancer. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. The content above comes from the network. if any infringement, please contact us to modify.